Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients.
Hannah ImlayAllison O Dumitriu CarcoanaCynthia E FisherBeatrice WongRobert M RakitaDaniel P FishbeinAjit P LimayePublished in: Transplant infectious disease : an official journal of the Transplantation Society (2020)
Cytomegalovirus disease remains a major cause of morbidity in D+R- HTR. In contrast to documented benefit in D+R- lung and kidney recipients, VGCV duration of 6 months was not associated with a lower incidence of CMV disease in D+R- HTR compared to 3-month duration and should be reconsidered in this patient population.